Literature DB >> 23325567

Neoadjuvant therapy for potentially resectable pancreatic cancer: an emerging paradigm?

Thomas B Brunner1.   

Abstract

Although neoadjuvant chemoradiotherapy has been tested for more than two decades and can be safely delivered to patients with non-metastatic pancreatic cancer, no randomised trials have been reported until now. Here we provide an overview of the first randomised trial in patients with potentially resectable cancer and of the latest developments in neoadjuvant therapy for this group of patients. It is necessary to continue to perform clinical trials in this field to accurately identify the effect on survival and quality of life in patients with potentially resectable, borderline resectable and unresectable pancreatic cancer. Aspects of imaging for restaging and clinical prognostic factors are also discussed given they will be useful instruments for future trials.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23325567     DOI： 10.1007/s11912-012-0291-3

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  41 in total

1.  The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.

Authors:  Seungmin Bang; Hye Won Chung; Seung Woo Park; Jae Bock Chung; Mijin Yun; Jong Doo Lee; Si Young Song
Journal:  J Clin Gastroenterol       Date:  2006 Nov-Dec       Impact factor: 3.062

2.  Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?

Authors:  Katia T Papalezova; Douglas S Tyler; Dan G Blazer; Bryan M Clary; Brian G Czito; Herbert I Hurwitz; Hope E Uronis; Theodore N Pappas; Christopher G Willett; Rebekah R White
Journal:  J Surg Oncol       Date:  2012-02-06       Impact factor: 3.454

3.  Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy.

Authors:  E P Tamm; E M Loyer; S Faria; C P Raut; D B Evans; R A Wolff; C H Crane; R A Dubrow; C Charnsangavej
Journal:  Abdom Imaging       Date:  2006-02-07

4.  Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis.

Authors:  Chang-Peng Zhu; Jian Shi; Yue-Xiang Chen; Wei-Fen Xie; Yong Lin
Journal:  Radiother Oncol       Date:  2011-05-14       Impact factor: 6.280

5.  Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas.

Authors:  J F Pingpank; J P Hoffman; E A Ross; H S Cooper; N J Meropol; G Freedman; W H Pinover; T E LeVoyer; A R Sasson; B L Eisenberg
Journal:  J Gastrointest Surg       Date:  2001 Mar-Apr       Impact factor: 3.452

6.  Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.

Authors:  Florence Huguet; Thierry André; Pascal Hammel; Pascal Artru; Jacques Balosso; Frédéric Selle; Elisabeth Deniaud-Alexandre; Philippe Ruszniewski; Emmanuel Touboul; Roberto Labianca; Aimery de Gramont; Christophe Louvet
Journal:  J Clin Oncol       Date:  2007-01-20       Impact factor: 44.544

Review 7.  Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.

Authors:  Sonja Gillen; Tibor Schuster; Christian Meyer Zum Büschenfelde; Helmut Friess; Jörg Kleeff
Journal:  PLoS Med       Date:  2010-04-20       Impact factor: 11.069

8.  Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review.

Authors:  R Le Scodan; F Mornex; N Girard; C Mercier; P-J Valette; M Ychou; F Bibeau; P Roy; J-Y Scoazec; C Partensky
Journal:  Ann Oncol       Date:  2009-06-05       Impact factor: 32.976

9.  Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy.

Authors:  H Golcher; T Brunner; G Grabenbauer; S Merkel; T Papadopoulos; W Hohenberger; T Meyer
Journal:  Eur J Surg Oncol       Date:  2008-01-10       Impact factor: 4.424

10.  Current oncological treatment of patients with pancreatic cancer in germany: results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society.

Authors:  Stefan Boeck; Christiane J Bruns; Mirja Sargent; Claus Schafer; Thomas Seufferlein; Karl-Walter Jauch; Volker Heinemann
Journal:  Oncology       Date:  2009-06-25       Impact factor: 2.935
View more
  4 in total

1.  The role of 18F-fluorodeoxyglucose positron emission tomography in the management of patients with pancreatic adenocarcinoma.

Authors:  Lujaien A Kadhim; Avani S Dholakia; Joseph M Herman; Richard L Wahl; Muhammad A Chaudhry
Journal:  J Radiat Oncol       Date:  2013-10-30

2.  Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.

Authors:  Brian A Boone; Jennifer Steve; Alyssa M Krasinskas; Amer H Zureikat; Barry C Lembersky; Michael K Gibson; Ronald G Stoller; Herbert J Zeh; Nathan Bahary
Journal:  J Surg Oncol       Date:  2013-09       Impact factor: 3.454

Review 3.  Update on the management of pancreatic cancer: surgery is not enough.

Authors:  Daniel Ansari; Adam Gustafsson; Roland Andersson
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

4.  Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets.

Authors:  Riccardo Casadei; Mariacristina Di Marco; Claudio Ricci; Donatella Santini; Carla Serra; Lucia Calculli; Marielda D'Ambra; Alessandra Guido; Antonio Maria Morselli-Labate; Francesco Minni
Journal:  J Gastrointest Surg       Date:  2015-07-30       Impact factor: 3.452
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.